Status:
COMPLETED
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
Lead Sponsor:
Janssen-Cilag B.V.
Conditions:
Anemia
Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer. Epoetin alfa and ...
Detailed Description
Anemia has been identified as a common complication and a widespread problem in the cancer population. Anemia is a condition in which a patient has below normal levels of hemoglobin, the substance in ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of solid tumors, multiple myeloma (Kahlers' disease), non-Hodgkin lymphoma or Hodgkins' disease
- Patients must already be receiving chemotherapy or start their first cycle within a week of enrollment
- Patients must receive either epoetin alfa or darbepoetin alfa treatment (expected treatment duration is at least 4 weeks)
Exclusion
- Patients not meeting all of the inclusion criteria for entry into the study
- Patients who cannot read the Dutch language and/or do not understand the Dutch Informed Consent Form
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
492 Patients enrolled
Trial Details
Trial ID
NCT00264108
Start Date
June 1 2005
End Date
February 1 2011
Last Update
May 7 2014
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
's-Hertogenbosch, Netherlands
2
Amstelveen, Netherlands
3
Amsterdam, Netherlands
4
Bergen op Zoom, Netherlands